A Constipation Drug Cleared Depression Brain Fog In About A Week, Scientists Are Calling It A Breakthrough

One of the most frustrating aspects of recovering from depression is that the mood often lifts before the brain fully follows. Many people who have successfully treated depressive episodes are left with lingering cognitive symptoms, poor memory, difficulty concentrating, and a persistent mental fog that can interfere with work, relationships, and daily life long after the emotional low has passed. A small clinical trial led by Dr. Angharad de Cates of the University of Birmingham in collaboration with researchers at the University of Oxford has produced an unexpected finding: a prescription drug currently approved for treating chronic constipation improved those cognitive symptoms measurably in people with a history of depression after just seven to ten days of use. The drug is called prucalopride, it is already licensed and available, and it works by activating a specific serotonin receptor called the 5-HT4 receptor, found in both the gut and the brain. The trial enrolled 50 adults who had previously experienced depression but had recovered at least six months before joining the study and were not taking any psychiatric medication at the time, and participants were randomly assigned to receive either the standard licensed dose of 2mg of prucalopride or a placebo.

At the end of the treatment period, participants taking prucalopride performed better on a battery of cognitive assessments than those who received the placebo, responding both faster and more accurately on tests of declarative memory, working memory, executive function, attention, and processing speed, with no significant side effects reported during the trial. Dr. de Cates said that cognitive problems and brain fog are an important and often overlooked feature of depression that can persist even when mood improves, and that the findings support further research into whether 5-HT4-targeting medications can be repurposed for depression or whether similar drugs can be developed to support people with depression and other mental health conditions. Professor Susannah Murphy of the University of Oxford, senior author of the study, noted that for many people recovery from depression is incomplete because difficulties with memory and concentration persist, and called the findings early evidence that this class of receptor agonists could help restore aspects of cognitive function. The study was published in the journal Psychological Medicine. The research team plans to continue investigating treatments for cognitive problems associated with major depressive disorder, noting that previous studies have also suggested 5-HT4 receptor agonists may reduce the risk of depression itself, raising the possibility that the drug class could provide multiple mental health benefits from a single mechanism.

Source:https://www.sciencedaily.com/releases/2026/07/260712011751.htm